Clinical Research Trials

Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.

Nonalcoholic Steatohepatitis (NASH)

Viking

VK2809 a phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of VK2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with biopsy proven non-alcoholic steatohepatitis with fibrosis(stage 1-3).

Learn More

Galectin

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.

Learn More

Inventiva

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3.

Learn More

Pfizer

The study aims to evaluate two, orally administered, investigational agents – PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).

Learn More

Novo Nordisk

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).

Learn More

Crohn’s

Eli Lilly(AMAM)

This is a Phase 3, multicenter, randomized, double-Blind, placebo- and active- controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in subjects who have moderately to severely active Crohn’s disease. Participants were divided into three study arms: the experimental group received intravenous (IV) and subcutaneous (SC) injections of mirikizumab; the group in the active comparator group received IV and SC injections of ustekinumab; the subjects in the placebo comparator group received placebo IV and SC injections.

Learn More

Arena(cultivate)

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.

Learn More

Screening Colonoscopy

Guardant Eclipse

The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer.  No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.

Learn More

Guardant Almanac

The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer.

Learn More

Eosinophilic Esophagitis

Arena Voyage

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.

Learn More

Primary Biliary Cholangitis (PBC)

Cymabay Response

To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo

Learn More

Genfit

The main objective of the study is to evaluate the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC and inadequate response or intolerance to Ursodeoxycholic Acid (UCDA)

Learn More

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.